Ryan Alling

Investment Advisor Representative

[Ryan Alling @ryan_alling]

Equity Research Analyst, Robert Driscoll, Ph.D., initiates on $CBIO with an #OUTPERFORM and $27 12-month price target. Lead asset CR-001 (PD-1 x VEGF bispecific) is shaping up as a fast-follower to ivonescimab, with real potential in NSCLC and beyond. https://t.co/vrROKJRuXU

[Ryan Alling @ryan_alling]

Genetics Guiding Through the Biotech $MAZE 🧬
Equity Research Analyst, Laura Chico, Ph.D., initiates coverage on the SF-based biopharma with an #OUTPERFORM rating and a 12-mo price target of $17.
🔗 Take a closer look: https://t.co/XfzID1Qi2O

[Ryan Alling @ryan_alling]

👣 “Follow the Telix of Oz…” — That’s the call from Equity Research Analyst David Nierengarten, Ph.D., as he initiates coverage on Telix Pharmaceuticals Ltd ($TLX) with an #OUTPERFORM rating and a $22 price target.
🔗 Dive into the details: https://t.co/usQwe2T9QD

[Ryan Alling @ryan_alling]

✨Rejuvenating the skin and clearing the air: Equity Research Analyst, Martin Fan, Ph.D. initiates coverage with an #OUTPERFORM rating and a $8 price target on Aclaris Therapeutics ($ACRS). Read more about Martin's coverage landscape here: https://t.co/rhLs82dHQ5.

[Ryan Alling @ryan_alling]

A fresh play on precision medicine: CAMP4 Therapeutics ($CAMP) advances a novel pipeline in rare metabolic and CNS disorders. Yun Zhong, Ph.D. initiates coverage with an #OUTPERFORM rating and a $8 price target.
Dive into Yun's coverage landscape here: https://t.co/WemVnHEX2Q.

[Ryan Alling @ryan_alling]

Validated biology, differentiated design – Jade Biosciences, Inc. ($JBIO) takes its shot in kidney disease. Laura Chico, PhD initiated coverage on $JBIO with an #OUTPERFORM rating, and $17 target.
Read more about Laura's coverage universe here: https://t.co/XfzID1Qi2O

[Ryan Alling @ryan_alling]

With inflation still impacting everyday costs, April is a great time to reassess spending habits and find new ways to stretch your dollars. Here are some ways to stay ahead of inflation and build your wealth. https://t.co/dkn0qQYHFe

[Ryan Alling @ryan_alling]

Equity Research Analyst, Matthew Bryson, initiated coverage on Sandisk Corporation ($SNDK) at #OUTPERFORM, setting a 12-month price target of $80. Matt and team "believe we could see a cyclical upturn... into the 2H of 2025." https://t.co/N2zdVex5qH

[Ryan Alling @ryan_alling]

As we head towards the April 15 filing deadline for your 2024 taxes, March is an important month to ensure that you have everything in order to file your return and to maximize your deductions and other benefits before filing. https://t.co/7PxI32mgmw

[Ryan Alling @ryan_alling]

At their most recent meeting in late January of this year, the Federal Reserve chose to leave interest rates at current levels.  Their next meeting is scheduled for mid-March and their decisions in this meeting could have implications for your finances. https://t.co/maASbxxmnH

[Ryan Alling @ryan_alling]

The beginning of the year is an ideal time to review your retirement savings to ensure that you are on track for the new year. Are your savings and investing strategies aligned with your retirement planning goals?
https://t.co/QG77LPZpPq

[Ryan Alling @ryan_alling]

As we settle into the new year, February is the perfect time to evaluate and fine-tune your budget for a strong financial start. These actionable tips can help you save more and spend smarter throughout the year. https://t.co/geZei6jVBA

[Ryan Alling @ryan_alling]

Equity Research Analyst, Yun Zhong, PhD, initiated coverage on Rocket Pharmaceuticals ($RCKT) at #OUTPERFORM, setting a 12-month price target of $32.00. Looking into the new year, Yun believes 2025 will be an "inflection" year for the company. https://t.co/CYLh51P0Al

[Ryan Alling @ryan_alling]

Equity Research Analyst, Scott Devitt, initiated coverage on Xometry, Inc. ($XMTR) at #OUTPERFORM, setting a 12-month price target of $48.00. Xometry is "well-positioned to take share within the global custom manufacturing industry," noted Scott. https://t.co/CDpU9f03qC

[Ryan Alling @ryan_alling]

The holiday season is upon us. A time for family, friends, reflection and scammers. Yes, scammers. Holiday scams can work in a number of ways, and it is important that we are aware and informed. https://t.co/bhih2rgRZZ

[Ryan Alling @ryan_alling]

Equity Research Analyst, Seth Basham, CFA®️ initiated coverage on Monro, Inc. ($MNRO) at #OUTPERFORM, setting a 12-month price target of $31.00. With recent pivots gaining momentum, Seth and his team "believe the industry and MNRO will return to growth." https://t.co/KArb3YsVz0

[Ryan Alling @ryan_alling]

Equity Research Analyst, Jay McCanless, initiated coverage on Hovnanian Enterprises, Inc ($HOV) at #NEUTRAL, setting a 12-month price target of $155.00. Jay and his team "believe the shares reflect the improved balance sheet." https://t.co/DLjSURnwSh

[Ryan Alling @ryan_alling]

Equity Research Analyst, Richard Anderson, initiated coverage on Centerspace (CSR) at #NEUTRAL, setting a 12-month price target of $72.00. "CSR continues to evolve... to the pure-play multifamily platform that it has become." https://t.co/Hr6EcRRF0m

[Ryan Alling @ryan_alling]

Equity Research Analyst, Laura Chico, Ph.D., initiated coverage on Solid Biosciences Inc. ($SLDB) at #OUTPERFORM, setting a 12-month price target of $16.00. With shares trading "near a ~$200M valuation... we do see levers for shares to work higher." https://t.co/rbNCVCwVm7

[Ryan Alling @ryan_alling]

Equity Research Analyst, Scott Devitt, initiated coverage on eBay Inc. ($EBAY) at #NEUTRAL, setting a 12-month price target of $70.00. "eBay is now positioning the business for sustainable long-term growth through multiple initiatives," notes Scott. https://t.co/Sr8PVnWhGI